Literature DB >> 21969931

Health-related quality of life and 6 min walk distance in patients with idiopathic pulmonary fibrosis.

Geetika Verma1, Theodore Marras, Nouri Chowdhury, Lianne Singer.   

Abstract

BACKGROUND: Few studies have investigated the relationship between physiological outcomes and quality of life in patients with idiopathic pulmonary fibrosis (IPF). Health-related quality of life (HRQL) data may provide a valuable patient-centred outcome for the evaluation of interventions. Determination of which physiological and functional variables are associated with HRQL may facilitate interpretation of disease progression and impacts of therapy.
OBJECTIVES: To determine whether an association between Medical Outcomes Short-Form 36 and St George's Respiratory Questionnaire scores and other markers of disease severity exist, and to identify which physiological and functional variables are independently associated with HRQL.
METHODS: In a cross-sectional study, 137 patients with IPF completed HRQL surveys and underwent clinical assessment. Multiple linear regression analysis was used to determine the relationship between age, forced vital capacity, diffusing capacity of carbon monoxide, 6 min walk distance (6MWD) and oxygen requirement, and HRQL scores.
RESULTS: 6MWD was the only functional measure of disease severity significantly associated with all domain scores of the St George's Respiratory Questionnaire and the Medical Outcomes Short-Form 36 physical component summary score.
CONCLUSIONS: 6MWD was associated with HRQL among patients with IPF. This highlights the importance of 6MWD not only as a prognostic indicator in IPF, but also a predictor of HRQL and a meaningful outcome for patients.

Entities:  

Mesh:

Year:  2011        PMID: 21969931      PMCID: PMC3267607          DOI: 10.1155/2011/109635

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  35 in total

1.  Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial.

Authors:  Ganesh Raghu; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Roland M du Bois; Joseph A Lasky; Michiel Thomeer; James P Utz; Rezaul K Khandker; Lawrence McDermott; Saeed Fatenejad
Journal:  Am J Respir Crit Care Med       Date:  2008-07-31       Impact factor: 21.405

2.  High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

3.  Normal values for the ratio of one-second forced expiratory volume to forced vital capacity.

Authors:  J F Morris; W P Temple; A Koski
Journal:  Am Rev Respir Dis       Date:  1973-10

4.  Attachment for automated single breath diffusing capacity measurement.

Authors:  E A Gaensler; A A Smith
Journal:  Chest       Date:  1973-02       Impact factor: 9.410

5.  The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.

Authors:  Jeffrey J Swigris; Frederick S Wamboldt; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Kevin K Brown
Journal:  Thorax       Date:  2009-12-08       Impact factor: 9.139

6.  Health-related quality of life in patients with idiopathic pulmonary fibrosis--cross-sectional and longitudinal study.

Authors:  Hiromi Tomioka; Kazufumi Imanaka; Kimio Hashimoto; Hironobu Iwasaki
Journal:  Intern Med       Date:  2007-09-14       Impact factor: 1.271

7.  The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.

Authors:  Jeffrey J Swigris; Kevin K Brown; Juergen Behr; Roland M du Bois; Talmadge E King; Ganesh Raghu; Frederick S Wamboldt
Journal:  Respir Med       Date:  2009-10-07       Impact factor: 3.415

8.  Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1).

Authors:  G Raghu; T E King; J Behr; K K Brown; R M du Bois; I Leconte; S Roux; J Swigris
Journal:  Eur Respir J       Date:  2009-08-13       Impact factor: 16.671

9.  BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Jürgen Behr; Kevin K Brown; Roland M du Bois; Lisa Lancaster; Joao A de Andrade; Gerd Stähler; Isabelle Leconte; Sébastien Roux; Ganesh Raghu
Journal:  Am J Respir Crit Care Med       Date:  2007-09-27       Impact factor: 21.405

10.  Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives.

Authors:  Jeffrey J Swigris; Anita L Stewart; Michael K Gould; Sandra R Wilson
Journal:  Health Qual Life Outcomes       Date:  2005-10-07       Impact factor: 3.186

View more
  13 in total

1.  Sleep disorders and health-related quality of life in patients with interstitial lung disease.

Authors:  Maria Mavroudi; Despoina Papakosta; Theodore Kontakiotis; Kaliopi Domvri; George Kalamaras; Vasiliki Zarogoulidou; Paul Zarogoulidis; Paschalina Latka; Haidong Huang; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Sleep Breath       Date:  2017-10-16       Impact factor: 2.816

Review 2.  The psychometric properties of the St George's Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review.

Authors:  Jeffrey J Swigris; Dirk Esser; Craig S Conoscenti; Kevin K Brown
Journal:  Health Qual Life Outcomes       Date:  2014-08-20       Impact factor: 3.186

Review 3.  Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis.

Authors:  Amy L Olson; Kevin K Brown; Jeffrey J Swigris
Journal:  Patient Relat Outcome Meas       Date:  2016-05-17

4.  Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry.

Authors:  Michael Kreuter; Jeff Swigris; David Pittrow; Silke Geier; Jens Klotsche; Antje Prasse; Hubert Wirtz; Dirk Koschel; Stefan Andreas; Martin Claussen; Christian Grohé; Henrike Wilkens; Lars Hagmeyer; Dirk Skowasch; Joachim F Meyer; Joachim Kirschner; Sven Gläser; Felix J F Herth; Tobias Welte; Claus Neurohr; Martin Schwaiblmair; Matthias Held; Thomas Bahmer; Marion Frankenberger; Jürgen Behr
Journal:  Respir Res       Date:  2017-07-14

5.  The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.

Authors:  Alex Diamantopoulos; Emily Wright; Katerina Vlahopoulou; Laura Cornic; Nils Schoof; Toby M Maher
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

6.  Reliability and Validity of the 6-Minute Walk Test in Hypophosphatasia.

Authors:  Dawn Phillips; Ioannis C Tomazos; Scott Moseley; Gil L'Italien; Hugo Gomes da Silva; Sergio Lerma Lara
Journal:  JBMR Plus       Date:  2019-03-01

7.  Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis.

Authors:  Hayley C Warsinske; Amanda K Wheaton; Kevin K Kim; Jennifer J Linderman; Bethany B Moore; Denise E Kirschner
Journal:  Front Pharmacol       Date:  2016-06-23       Impact factor: 5.810

8.  Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Toshiaki Matsuda; Hiroyuki Taniguchi; Masahiko Ando; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Koichi Nishimura; Osamu Nishiyama; Koji Sakamoto; Yoshinori Hasegawa
Journal:  Intern Med       Date:  2017-07-01       Impact factor: 1.271

9.  Validation of the COPD Assessment Test (CAT) in patients with idiopathic pulmonary fibrosis.

Authors:  Heidi Kjeldgaard Grufstedt; Saher Burhan Shaker; Hanne Konradsen
Journal:  Eur Clin Respir J       Date:  2018-10-16

Review 10.  A systematic review of literature to evaluate the burden of physical and psychological symptoms and palliative care in patients diagnosed with idiopathic pulmonary fibrosis.

Authors:  M F van Jaarsveld; L Gwyther
Journal:  Afr J Thorac Crit Care Med       Date:  2019-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.